GND-04
Oncology
IND-EnablingActive
Key Facts
About Gandeeva Therapeutics
AI‑driven cryo‑EM platform creates molecular glues for oncology targets.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |
| Bendamustine Intermediate | AR Life Science | Commercial |
| Imatinib Intermediate | AR Life Science | Commercial |
| Dasatinib Intermediate | AR Life Science | Commercial |
| Personalized Medicine Assays (Patient-Derived Explants) | Aurita Bioscience | Research-Use Only |
| CDK2-CyclinE1 & CDK2-CyclinA2 Assay | Aurora Biolabs | Commercial |